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Abstract
Any given single nucleotide polymorphism (SNP) in a genome may have little or no functional impact. A biologically
significant effect may possibly emerge only when a number of key SNP-related genotypes occur together in a single
organism. Thus, in analysis of many SNPs in association studies of complex diseases, it may be useful to look at
combinations of genotypes. Genes related to signal transmission, e.g., ion channel genes, may be of interest in this respect
in the context of bipolar disorder. In the present study, we analysed 803 SNPs in 55 genes related to aspects of signal
transmission and calculated all combinations of three genotypes from the 36803 SNP genotypes for 1355 controls and 607
patients with bipolar disorder. Four clusters of patient-specific combinations were identified. Permutation tests indicated
that some of these combinations might be related to bipolar disorder. The WTCCC bipolar dataset were use for replication,
469 of the 803 SNP were present in the WTCCC dataset either directly (n=132) or by imputation (n=337) covering 51 of our
selected genes. We found three clusters of patient-specific 36SNP combinations in the WTCCC dataset. Different SNPs were
involved in the clusters in the two datasets. The present analyses of the combinations of SNP genotypes support a role for
both genetic heterogeneity and interactions in the genetic architecture of bipolar disorder.
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Introduction
Bipolar disorder (BD) is a severe psychiatric disease generally
characterized by repeated manic and depressive episodes. The
time of onset varies, but it usually begins between the ages of 15
and 25 years, affecting men and women equally with a lifetime
prevalence of 1.5% [1]. Family, twin, and adoption studies have
shown that genetic factors contribute to BD, but the involved
genes have not yet been identified. This may partly be explained
by a genetic architecture characterized by both genetic heteroge-
neity (at the population level) and polygenic interactions (at the
level of the individual) [2–5]. Locus heterogeneity in a disease may
occur when dysfunctions in different mechanisms each produce
the symptoms characterising the phenotype.
In the search for disease-associated genes, high-throughput
genotyping methods have allowed analysis of a large number of
single nucleotide polymorphisms (SNPs), but most of these studies
have used single-locus analysis strategies. Yet, many common
diseases have complex aetiologies that may involve combinations
of SNPs from different genes and, possibly, different combinations
within the population of affected individuals. The growing interest
in interactions and their contribution to risk for complex diseases
has resulted in a search for methods of calculating disease-related
interactions of two or more SNPs [6]. Most of these methods are
theoretical, and many concentrate on finding combinations of two
SNPs [7–10]. Only a few studies have looked at combinations of
more SNP genotypes; for example, Xie et al. [11], in a study of
oesophageal cancer, analysed SNP genotypes from genes related to
DNA repair mechanisms and liver function and identified
combinations of genotypes relevant to the disease. In the quest
for alternative approaches in the search for interacting SNPs,
interest has grown in pathways with an enrichment of associated
signals [12–15]. These methods are robust to the detection of
enrichment that derives from genetic heterogeneity at the
population level or from gene- or protein-interactions at the
individual level.
In BD, hyperactivity is the main symptom of the manic phase,
and this clinical phenotype may reflect altered activity at the
cellular or molecular level that leads to faster signal transmission in
the brain. Numerous mechanisms are involved in signal
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many different dysfunctions in mechanisms relevant to signal
transmission velocity in the nervous system; this concept is in
agreement with the genetic heterogeneity of BD [2,3]. We
previously suggested that propagation of nerve impulses may be
faster in mania than in a normal affective state [16], which is in
agreement with a number of similar hypotheses proposing mania
as a disorder of ionic conductance of nerve cell membranes [17],
nerve cell excitability [18,19], action potential firing [20], neuronal
hypersynchronization [21], changes in sodium pump number [22],
membrane abnormalities [23], and cortical instability [24].
Furthermore, the suggestion that nervous system hyperactivity
may play a role in BD is in accordance with the fact that several
drugs used to treat epilepsy are effective in the treatment of mania.
We have investigated genes (1) related to the action potential,
where we focused on genes related to the architecture of the sodium
channels in the nodes of ranvier and CNS myelination [19,25–29].
Among these genes, we have selected those (2) that occur in loci
considered to be of interest with respect to BD, as indicated by
linkage analyses [30,31]; (3) that encode proteins that are targets for
mood-stabilizing drugs [29,31,32]; or (4) that previous studies have
shown are associated with BD [19,26,29,31]. Many genes in this
group are related to ion channels, an observation that agrees with
the finding of Askland et al. [12] that variation in ion channel genes
may contribute to susceptibility to BD.
In the present study, we analysed 803 SNPs in 55 genes related
to aspects of signal transmission and calculated all combinations of
three genotypes (the normal homozygote, the heterozygote, and
the variant homozygote, respectively) from the 36803 SNP
genotypes. We likewise calculated all combinations with three
SNP genotypes from the genome wide association study (GWAS)
performed by the Wellcome Trust Case Control Consortium
(WTCCC) [33] using SNPs analysed in both datasets. We found
132 SNPs that were genotyped in both studies, by imputation we
obtained additional 337 SNPs with a good quality, thus 469 SNPs
were among our 803 SNPs and available for validation.
Results
Calculation of single SNP association
803 SNPs in 55 genes (see Table 1) were analysed and a Chi-square
test (or Fishers exact test when appropriate) was performed for each
SNP. The genotype distribution was significantly different (p,0.05)
between control persons and patients for 86 SNPs (see Table S1), but
none remained significant after a Bonferroni correction.
Combination of two SNPs
Combinations of two SNPs from 803 SNPs results theoretically
in 803!/2!(80322)!69=2,898,027 combinations, whereas the
actual number in the material was 2,770,033 combinations. Chi-
square test for each of these combinations was not performed, but
1000 permutation tests showed that combinations found exclu-
sively in the patients (161,070 combinations) could be random.
Combinations with three SNPs
Combinations of three SNP genotypes from the 803 SNPs results
theoretically in 803!/3!(80323)!63
3=2,321,319,627 combinations
of three-SNP genotypes (in the following to be termed 3-
combinations) (Table 2). The actual number of 3-combinations of
genotypes found in our material (1962 individuals) was
1,985,613,130. Most, namely 1,719,002,329 of these 3-combina-
tions (87%) were common for both control persons and patients,
whereas 208,699,590 3-combinations were found in control persons
only, and 57,911,211 3-combinations were found in patients only
(Table 2). The number of patient-specific 3-combinations shared by
several patients decreases as the number of patients in a group
increases (Table 2). When the number of patients was nine or more,
only 1181 3-combinations of the 57,911,211 patient-specific 3-
combinations remained. In order to see if the subgroup of 1181 3-
combinations may be of importance for BD, 1000 permutation tests
ofthecompletematerialwerecalculated,anditwas foundthat 1181
3-combinations shared by nine or more patients might be a random
finding (found 113 times; p=0.11).
Among the 1181 3-combinations, many genotypes were part of
one or two 3-combinations and only a few genotypes occurred in
more than ten 3-combinations. However, we observed that four
genotypes (AVPR1B_rs33976516=1 (one indicate heterozygocity),
KCNN3_rs884664=2 (two indicate homozygosity for the minor
allele), CACNG2_rs2179871=2, KCNQ3_rs2469515=2) occurred
in 46, 45, 49, and 32 3-combinations, respectively (Figure 1–4). The
genotypes were all among the 86 SNPs showing a significantly
different distribution between control persons and patients (nominal
p-values were 0.013, 0.010, 0.023, and 0.017, respectively).
Futhermore; these four observed subgroups of 3-combinations
containedallthepatientsinthematerial(41,48,41,and 37patients,
respectively) having the four genotypes (Figure 1–4). Such
subgroups characterised by relatively many 3-combinations sharing
a defining genotype and containing all the patients having this
genotype are called clusters. In 1000 permutation tests, at least one
cluster of this type (with at least 37 pseudo-patients) were seen 42
times (p=0.042), two such clusters were seen 3 times (p=0.003),
and at least three or more clusters of this type did not occur once
(p,0.001). Relatively little overlap between the patients in the
clusters was observed, as only eleven of the patients were members
of two clusters, and no patient was a member of three or four
clusters. A total of 156 patients were involved in the four clusters.
All patients in a cluster shared the defining genotype, but nested
within the four clusters, eleven smaller subgroups were observed.
In these subgroups patients sharing the same defining genotype
(e.g. AVPR1B_rs33976516=1) also shared a second genotype (e.g.
ANK3_rs2288358) in combinations with four or more distinct third
SNPs (shown in Figure 1–4 as the boxes in the third column).
Considerable overlap between patients was found within these
subgroups. In 1000 permutation tests only 49 subgroups of this
type were found (p=0.049). Additionally, within this type of
subgroup, 12 even smaller subgroups were characterized by
having the third genotype in the 3-combinations contributed by
SNPs from the same gene (shown in Figure 1–4 as more SNP
numbers in the same box). These 12 small subgroups together
comprised 32 3-combinations. Only 19 3-combinations of this type
were found in 1000 permutation tests (p=0.019).
WTCCC data [33]
Of our 803 SNPs 132 were genotyped in the WTCCC bipolar
disorder dataset [33]. In order to obtain more SNPs, we
performed an imputation using impute2 on the chromosome
regions surrounding our selected genes. We could impute 651
SNPs of our 803 SNPs, but after removing SNPs with a low quality
we ended up with additional 337 SNPs, leaving 469 SNPs in
common between our material and the WTCCC.
Chi-square test (or Fishers exact test when appropriate) was
performed for each SNP. The genotype distribution was
significant different (p,0.05) between control persons and patients
for 51 SNPs (see Table S1), but none remained significant after a
Bonferroni correction. Five of the 51 SNPs were among the 86
significant SNPs in our material (see Table S1).
The theoretically number of 3-combinations from the 469 SNPs is
461,262,438, while the observed number was 287,931,183. Most,
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Gene Location Name and/or Function SNP Ref.
a
ANK3 10q21 Role for structure and function of nodes of Ranvier 84 25,28,29
AQP4 18q11.2–q12.1 Regulator of vasopression secretion 12 30,31
ATP1A2 1q21–q23 Na+/K+ ATPase alpha-2 subunit 10 30,32
ATP1A3 19q13.31 Na+/K+ ATPase alpha-3 subunit 3 29,30
AVPR1B 1q32 Arginine vasopressin receptor 1B 3 30,42
BACE1 11q23.2–q23.3 Regulation of the voltage dependent Na-channels. 10 30,40
BDNF 11p13 Involved in neuroplasticity and stress response 6 29–31
CACNG2 22q13.1 Neuronal calcium channel gamma subunit,
stabilize the channel in an inactive state
34 30,43
CAMKK2 12q24.2 Involved in activation of CREB1 10 30–32
CLDN11 3q26.2–q26.3 Role in myelinisation 3 26,30,31
CNTN1 12q11–q12 Cell adhesion molecule 30 25,32
CNTN2 1q32.1 Cell adhesion molecule 14 25,30
CNTNAP1 17q21 Contactin-associated protein, may be the
signaling subunit of contactin
2 25,28
CNTNAP2 7q35–q36 Cluster voltage-gated potassium channels,
localized at the juxtaparanodes
46 25,27,28,30
CREB1 2q34 Transcription factor 5 28,30,32
DLG4 17p13.1 Neuronal development, recruited into potassium channel clusters 6 27,30,32
ERBB4 2q33.3–q34 Neuregulin-1 receptor, involved in mitogenesis and differentiation 6 30,41
GSK3B 3q13.3 Neuronal cell development (Related to lithium respons) 4 29,31
IMPA2 18p11.2 Inositol monophosphatase (Related to lithium respons) 16 29,30
KCNA1 12p13.32 Voltage-gated delayed potassium channel 2 25,27,30
KCNA2 1p13 Voltage-gated delayed potassium channel, delayed rectifier class 2 25,27,30
KCNC1 11p15 Mediates the voltage-dependent potassium ion
permeability of excitable membranes
9 30,38
KCNC2 12q14.1 Mediates the voltage-dependent potassium ion
permeability of excitable membranes
26 30,32
KCNC3 19q13.3–q13.4 Mediates the voltage-dependent potassium ion
permeability of excitable membranes
5 30,38
KCNN3 1q21.3 Potassium conductance Ca-activited channel,
regulate neuronal excitability
29 30
KCNQ2 20q13.3 Voltage-gated potassium channel plays a role in
the regulation of neuronal excitability
12 25,29,30
KCNQ3 8q24 Voltage-gated potassium channel plays a role in
the regulation of neuronal excitability
30 25,30
MAG 19q13.1 Central role i myelinisation, involved in
myelin-neuron cell-cell interactions
8 26,30
MAP2 2q34–q35 Microtubule-associated protein, involved in neurogenesis 16 30,31
MBP 18q23 Major constituent of the myelin sheath of
oligodendrocytes in the nervous system
23 26,30
MCHR1 22q13.2 Inhibit cAMP accumulation stimulate intracellular Ca-flux 3 26,29,30
MCTP2 15q26.2 Intercellular signal transduction 3 30
MOG 6p22.1 Involved in completion and maintenance of the
myelin sheath and in cell-cell communication
72 6
NCAM1 11q23.1 Neural cell adhesion molecule 1 34 25,28–30
NFASC 1q32.1 Cell adhesion; organization of the axon initial
segment (AIS) and nodes of Ranvier
31 25,28,30
NRCAM 7q31.1–q31.2 Ankyrin-binding protein is involved in neuron-neuron adhesion 37 25,29,30
NRG1 8p12 Associated with ERBB receptors 38 26,29,30,41
NTRK1 1q21–q22 Neurotrophic tyrosine kinase, receptor, type 1 1 30,39
OLIG2 21q22.11 Oligodendrocyte lineage transcription factor 2 3 26,30
P2RX7 12q24 Ligand-gated ion channel 19 29,30
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a
PDE4B 1p31 Phosphodiesterase 4B, cAMP-specific 3 30,32
PPP2R2C 4p16.1 Protein phosphatase 2, regulatory subunit B, gamma isoform 27 29,30
SCN1B 19q13.1 Sodium channel beta subunit, propagation of nerveimpulses,
binding to contactin
3 25,28,30
SCN2A 2q23–q24 Sodium channel alpha subunit, generation and propagation
of action potentials in neurons
12 25,28,30
SCN2B 11q23 Sodium channel, voltage-gated, type II, beta 5 25,28,30
SCN4B 11q23.3 Sodium channel, voltage-gated, type IV, beta 6 25,28,30
SCN5A 3p21 Sodium channel, voltage-gated, type V, alpha subunit 5 25,28,30
SCN8A 12q13 Sodium channel, voltage gated, type VIII, alpha subunit,
associated with ANK3
15 25,28,30
SLC12A6 15q13–q15 Electroneutral potassium-chloride cotransporter 3 10 29,30
SPTBN4 19q13.13 Involved in location of specific membrane proteins in
polarized regions of neurons
15 25,28,30
TBR1 2q24 Transcription factor, critical for early cortical development 3 30,31
TNC 9q33 Regulation of Na channels. Interaction with CNTN1 28 25,30
TNR 1q24 Extracellular matix protein expressed primarily in the
central nervous system
16 25,30
TRPM2 21q22.3 Transient receptor potential cation channel, subfamily M, member 2 9 29,30
YWHAH 22q12.3 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide
4 29,30
a)As of September 2007, when our SNP selection ended prior to analysis.
doi:10.1371/journal.pone.0023812.t001
Table 1. Cont.
Table 2. Number of combinations of three SNP genotypes (3-combinations) found in 1355 control persons and 607 bipolar
patients.
Number of 3-combinations
Theoretical number with 803 SNPs 2,321,319,627
Found in the present material of 803 SNPs 1,985,613,130
Common for control persons and patients 1,719,002,329
Found in the control persons only 208,699,590
Found in the patients only 57,911,211
Found in single patients only and no control person 45,285,770
Common for 2 patients and no control person 9,557,540
Common for 3 patients and no control person 2,277,107
Common for 4 patients and no control person 578,259
Common for 5 patients and no control person 156,343
Common for 6 patients and no control person 41,019
Common for 7 patients and no control person 10,990
Common for 8 patients and no control person 3,002
Common for 9 patients and no control person 826
Common for 10 patients and no control person 261
Common for 11 patients and no control person 70
Common for 12 patients and no control person 22
Common for 13 patients and no control person 2
Common for 9 or more patients and no control person 1,181
doi:10.1371/journal.pone.0023812.t002
Combinations of SNPs in BD
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23812Figure 1. Cluster defined by AVPR1B rs33976516=1
a. a) 0: Normal homozygote; 1: Heterozygote; 2: Variant homozygote.
doi:10.1371/journal.pone.0023812.g001
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a. a) 0: Normal homozygote; 1: Heterozygote; 2: Variant homozygote.
doi:10.1371/journal.pone.0023812.g002
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a. a) 0: Normal homozygote; 1: Heterozygote; 2: Variant homozygote.
doi:10.1371/journal.pone.0023812.g003
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a. a) 0: Normal homozygote; 1: Heterozygote; 2: Variant homozygote.
doi:10.1371/journal.pone.0023812.g004
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whereas 16,762,350 3-combinations were found in control persons
only, and 23,691,570 3-combinations were found in patients only.
Using the above mention criteria for a cluster, three clusters were
observed among the patient-specific 3-combinations. The defining
genotypes were NFASC_rs12737855=2, NFASC_rs7519658=2
and ANK3_rs6479700=2, containing 124, 135 and 182 combina-
tions, and 159, 150 and 142 patients, respectively (data not shown).
All three genotypes were among the 51 significant SNPs. In 1000
permutation tests, at least one cluster of this type (with at least 142
pseudo-patients) were seen 49 times (p=0.049), two such clusters
were seen 3 times (p=0.003), and at least three clusters of this type
did not occur once (p,0.001).
Within the three clusters, we again observed smaller subgroups
where patients also shared the second genotype in six or more
combinations, and there were a considerable overlap between the
patients involved in these subgroups. In 1000 permutation tests
only 29 of such subgroups were found (p=0.029).
There was a substantial overlap between the patients in the two
clusters with the defining SNPs belonging to the NFASC gene
(n=134), while only a limited number of patients belonging to the
third cluster (defined by ANK3_rs6479700) were present in the two
other clusters (n=10 and n=8, respectively, where eight were part
of all three clusters).
Discussion
Complex diseases may be associated with combinations of
SNPs. A number of methodological and theoretical studies have
addressed this statistical and data-mining challenge [7–15,34], but
clinical investigations using combinations of several SNPs are rare
[11]. The problem with combinations is the large numbers
created, which is computationally demanding, especially when
permutation tests are used as a statistical method. Thus in the
present study, with 803 SNPs and combinations of no more than
three SNP genotypes at a time, we found 1,985,613,130 3-
combinations, close to the theoretical maximum of 2,321,319,627
3-combinations. Due to the relative low number of subjects and
genetic factors as allele frequency and non-independence of SNPs
located in the same gene region, we had expected to find a smaller
number of 3-combinations.
In an attempt to identify 3-combinations related to BD, only 3-
combinations found exclusively in the patient group were
examined in more detail in this study, meaning that only
combinations with 100% penetrance were examined. Among the
1,7 billion 3-combinations common for control persons and
patients many may be associated with disease; these combinations
will be analysed separately. In the 58 million 3-combinations
found exclusively in the patients, 45 million were singularities
(found in one person only), raising the possibility that they were
random. Following this line of reasoning, the 1181 3-combina-
tions, shared by nine or more patients and no control person, may
be the most promising in relation to BD, but permutation tests
showed that these also might have been random. However, 172 of
these 3-combinations were located in four clusters each char-
acterised by a defining genotype, and by inclusion of all patients
having this genotype. Occurrence of three or more clusters of this
type was not found once in 1000 permutation tests, indicating that
at least some 3-combinations in the clusters may be related to BD.
In addition, subgroups within the four clusters also shared the
second genotypes, and some had the third genotype in the 3-
combinations located in the same gene, suggesting that accumu-
lation of several genotypes in a single gene may be important for
the disease susceptibility in some cases.
We found only 5 nominally significant SNPs in common between
the Scandinavian material and the WTCCC material (see Table
S1), indicating heterogeneity between the two samples. A cluster
with the same defining genotype as in one of the four clusters
observed in our material could not be found in the WTCCC
material, as none of the four defining SNPs were present among the
132 genotyped SNP or the 337 imputated SNPs in the WTCCC
dataset. However, three significant clusters were found. Again three
of more clusters were not seen once in 1000 permutation tests. Also
nesting 3-combinations sharing the two first genotypes was present
in the WTCCC dataset (p=0.029). An overlap in the clusters
observed in the two dataset were not see in the 3-combinations
exclusively found in patients, but may be found in the much larger
group of combinations common for control persons and patients.
An examination of individual patient data in both sample sets shows
that most of the patients carry many of the 3-combinations in the
clusters although none had exactly identical pattern of 3-combina-
tions, raising the possibility that each patient has a unique genetic
background for the disorder. The subgroups of 3-combinations with
overlap in patients, sharing two genotypes in more than four 3-
combinations, are interesting because different SNP as the third
(sometimes even from the same gene (in some cases in close LD)) leads
to an accumulation of several genotypes in small group of patients.
Such an accumulation may be important for the disease susceptibility.
Askland et al. [12] found that although the data from two large
independent GWAS [33,35] both pointed to ion channel genes as
important for BD, only a modest overlap between the two studies was
found for the involved genes. The authors suggested that prominent
genetic heterogeneity might explain this modest overlap [12]. The
present analyses of the 3-combinations of SNP genotypes support the
explanation that genetic heterogeneity is prominent in the genetic
architecture of BD. This heterogeneity is illustrated by the many
patient-specific 3-combinations of SNP genotypes, some of which may
be important for BD. The selection of genes in this study is based on
their relation to some aspects of signal transmission in the brain, so
obviously any combination of genotypes might be related to this
function. However, a more narrow relationship may be seen in the
cluster defined by KCNQ3 rs2469515 (Figure 4) together with ANK3
rs12049756 and three different SNPs from SCN2A (rs12469667,
rs3769949, and rs997508); as the proteins translated from these genes
all are located in the node of ranvier [25]. Similarly, in the largest
subgroup defined by CACNG2 rs2179871 (Figure 3), and involving 13
combinations with KCNN3 rs6426998 as the second SNP, many of the
nine different genes involved as the third SNP are implicated in the
architecture of the sodium channels in the node of ranvier (e.g.
SPTBN4, CNTNAP2, NFASC, SCN2A and ANK3).
Our study indicates that BD may show extreme genetic
heterogeneity at the population level. At the same time the many
3-combinations in each patient may support gene-gene interactions
or epistasis important for BD. However, such interactions probably
will involve genes not analysed in the present study. A more
profound discussion of functional connections between the genes
participating in a combination remain speculative and is prelimi-
nary until more genes related to signal transmission are analysed
and combinations of more than three genotypes can be carried out.
The pronounced genetic heterogeneity and the number of possible
interactions on the individual level both suggest that the biology of
BD may be very complex; but on the other hand, if the genotypes
behind the heterogeneity are associated with a limited number of
functions the degree of complexity may be decreased.
Future direction
In this work we have looked at the combinations of three SNP
genotypes that were observed in patients only. The next step is to
Combinations of SNPs in BD
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23812look at the much larger number of combinations seen in both
patients and controls. However, this may involve calculations of
combinations with more than three SNP genotypes.
Materials and Methods
Patient sample
This study is based on two independent case-control samples
from Norway and Denmark, included in the Scandinavian
Collaboration of Psychiatric Etiology (SCOPE). The Danish
sample consisted of 220 bipolar patients from the Copenhagen
area, 162 bipolar patients in Jutland, and 1133 control
participants. The sample from Norway included 222 controls
and 225 bipolar patients. Thus, a total of 607 unrelated patients
and 1355 unrelated healthy control participants were included.
The Norwegian patients had been diagnosed according to the
DSM-IV and the Danish patients according to ICD-10. The
Norwegian and Danish healthy controls and cases have been
described in more detail elsewhere [36,37]. The Norwegian
Scientific-Ethical Committees, the Norwegian Data Protection
Agency, the Danish Scientific Committees, and the Danish Data
Protection Agency approved the study. All patients gave written
informed consent prior to inclusion in the project.
Genes
The genes, shown in Table 1, were selected based on the
following criteria: (1) literature relating corresponding functional
proteins to various aspects of the action potential (with focus on the
architecture of the sodium channels in the nodes of ranvier and
CNS myelination) [25–29,38–41]; (2) occurrence in loci associated
with BD, as indicated by linkage analyses [30,31]; (3) encoding of
corresponding proteins that are targets for mood stabilizing drugs
[29,31,32]; and (4) identification in previous studies showing an
association with BD [26,29,31,41–43]. Additional we used
information from different internet sources (www.ncbi.nlm.nih.
gov/Database/; www.ensembl.org/index.html; www.pubgene.
org; www.ensembl.org/index.html; www.string.embl.de; www5.
appliedbiosystems.com/tools/pathway/all_pathway_list.php; www.
reactome.org).
We prioritized genes fulfilling more than one criterion, but
realize that other genes fulfil the criteria and thus could have been
included instead. The genotyping were planned in the autumn of
2007 and preformed in the spring 2008.
SNP selection and genotyping
To cover most of the common variants with tagSNPs, we used a
structured gene-wide approach, based on the HapMap CEU
population. TagSNP selection was performed at the HapMap
website using pair-wise tagging, with r
2$0.8 [44] (www.hapmap.
org; HapMap Data Rel 22/phaseII Apr07) and minor allele
frequency (MAF)$0.05. Some SNPs (some with MAF,0.05) were
selected if they resulted in a missense mutation or if they had been
linked to BD. Not all selected tagSNP were genotyped, and
exclusion was attributable to the following reasons: (1) a design
score ,0.4 for the Illumina Platform (n=109); (2) failure during
the genotyping analysis (n=76); or (3) being discarded during
quality control for several reasons [sample call rate ,90%, more
than three clusters seen in the result, and/or SNP not in Hardy-
Weinberg equilibrium (HWE; p,0.001) (n=94)]. This resulted in
803 SNP for analyses as described below.
Genomic DNA was extracted from whole blood. Most (796) SNPs
weregenotypedusingtheGoldenGate1536plexassay(IlluminaInc.)
on Illumina BeadStation 500GX at the SNP Technology Platform,
Uppsala University, Sweden (www.genotyping.se), accredited by the
Swedish accreditation agency SWEDAC, and approved according
to a quality system based on the international SS-EN ISO/IEC
17025 standard. For the subset of SNPs used in this study, the
reproducibility was 99.999% (there was one duplicate error in
70,098duplicategenotypecalls),andtheaveragesamplecallrateper
SNP assay was 99.6%. The four SNPs in YWHAH and the three
SNPs in SCN1B were genotyped using TaqMan genotyping assays
according to the manufacturer’s instructions. For these, the
reproducibility was 99.72%, and the average sample call rate per
SNP assay was 98.4%.
Statistics and data processing
The samples were tested for population stratification by
calculating the gene-based overall fixation index FST using
Arlequin Software [36,37]. The statistical significance of single
genotype distribution was assessed using the Chi-square or Fisher’s
exact test, whereas patterns of SNP combinations were assessed by
permutation tests.
Combinations of genotypes were calculated using array-based
mathematical methods [45,46], where data are represented
geometrically, hereby facilitating parallel processing, which was
performed using programs from Genokey (www.genokey.com) and
Dyalog (www.dyalog.com).
Each of the 1000 permutation tests (in our dataset) were
performed as follows: 1) A permutation of the entire population
(i.e. indicies 1 to 1962) is determined. The result is a new vector
with all indices 1 to 1962 in random order. 2) 607 random
‘‘patients’’ are selected, and the remaining 1355 individuals are
‘‘controls’’. 3) The cluster analysis on the 607 ‘‘patients’’ and 1355
‘‘controls’’ is determined using exactly the same methods as
previously on the biological samples. Likewise, permutation tests
were performed in the WTCCC dataset with 1998 random
‘‘patients’’ and 1500 random ‘‘controls’’.
Imputation of WTCCC data
We obtained genotype data on the bipolar patients
(n=1998) and the UK blood service control group (n=1500)
from the WTCCC data [33]. We searched for SNPs genotyped
in both samples and found 132. To get more SNPs in common
for the two dataset, we performed imputation using Impute2
(mathgen.stats.ox.ac.uk/impute/impute_v2.html) [47,48] of
SNPs in the chromosome regions around our selected genes
(with at minimum of 500 kb surrounding area). We used both
the provided hapmap3 dataset and the 1000 genome project
samples as reference samples resulting in ‘‘Ne’’ to be 15000.
We used default setting with the following exception: we set
‘‘iter’’ to 40 and ‘‘k’’ to 100 to get better genotypes, we selected
a call thresh hold to be 0.9, and set the result to include only
the SNPs, that we have genotyped. Prior to the imputation we
exclude SNPs from the WTCCC dataset, that WTCCC had
excluded due to low genotyping quality. We only include
imputated SNPs with a certain (more than 80% probability for
a given genotype) genotype calling in more than 80% of the
subjects.
Supporting Information
Table S1 Nominal significant SNPs in the present
sample as well as in the WTCCC dataset.
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